Skip to main content

Table 1 Patient and disease characteristics

From: Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment

FEATURES:Number of patients (total 8):
GENDER:
 Male5
 Female3
AGE (years):
 Mean68.4
 Range57–80
ECOG PERFORMANCE STATUS:
 0–16
 2–32
PRIMARY TUMOR SITE:
 Skin1
 Breast1
 Lung6
HISTOLOGY:
 Adenocarcinoma (lung)3
 Adenocarcinoma (breast)1
 Squamous (lung)3
 Malignant melanoma1
TREATED BULKY TUMOR SITE:
 Lung primary6
 Neck lymph node metastasis (skin melanoma)1
 Bone metastasis (breast)1
BULKY TUMOR PATIENTS WITH DISTANT OLIGOMETASTASES:3
 Lung primary(1), malignant melanoma (1), Breast(1), 
BULKY TUMOR PATIENTS WITH LYMPH NODE METASTASES ONLY:5
 Lung primary(5)
UNRESCTABLE BULKY TUMOR DIAMETER: mean/range (cm)10.1/6.6–13.8
UNRESCTABLE BULKY TUMOR VOLUME: mean/range (cm3)375.4/121.5–901.8
TARGETED BULKY TUMOR HYPOXIC SEGMENT: mean/range (cm3)124.7/41.9–442.9
SYSTEMIC THERAPY (exclusively before SBRT-PATHY)
 Chemotherapy1
 Immunotherapy1
SYMPTOMS related to bulky disease:
 Pain6
 Dyspnea7
 Cough5
 Haemoptysis2
PATIENTS TREATED AT “MOST FAVOURABLE” DAY:4
 Lung primary: squamous(1) and adenocarcinoma(1)2
 Neck lymph node metastasis of malignant melanoma of the skin1
 Bone metastasis of breast adenocarcinoma1
PATIENTS TREATED AT “LEAST FAVOURABLE” DAY:4
 Lung primary: squamous(2) and adenocarcinoma(2)4
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, SBRT-PATHY SBRT PArtial Tumor irradiation of the HYpoxic segment, LLr lower lobe right, LLl lower lobe left, ULr upper lobe right, ULl upper lobe left, BTV bystander tumor volume (hypoxic segment), CHT chemotherapy, N.A. not applicable